• DeutschDeutsch
  • EnglishEnglish
    • ABOUT
    • ONCOLOGY
    • PRODUCT
    • NEWS
    • INQUIRIES
    • VISIT US
ONCOSCIENCE > NEWS

ARCHIVES

  • June 2022
  • May 2022
  • November 2020
  • March 2019
  • October 2018
  • November 2017
  • August 2017
  • April 2016
  • July 2015
  • July 2010
  • October 2009
  • October 2008
  • April 2008
  • October 2007
  • September 2007
  • June 2007
  • September 2005
  • March 2005
  • January 2005
  • October 2004
  • August 2004
  • June 2004
  • March 2004
  • November 2003

SEARCH

  • Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.

    Oncoscience | November 17th, 2017

    New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab...

  • legal form changed

    Oncoscience | August 22nd, 2017

    We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....

  • Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba

    Oncoscience | April 7th, 2016

    At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...

  • Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG

    Oncoscience | July 22nd, 2015

    The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe. Transactio...

  • Oncoscience AG and GenIlac agree on cooperation terms in Turkey

    Oncoscience | July 7th, 2010

    Oncoscience, Wedel and GenIlac, Ankara agree on cooperation in Turkey for Nimotuzumab(Theraloc®), an EGFr antibody, whi...

Posts navigation

Previous 1 2 3 Next
    • LEGAL NOTICE

©Copyright of Oncoscience GmbH 2023

Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung